Activity
6K followers
-
Drew Fine shared thisVery interesting webinar this Wednesday with the experts from Croma-Pharma presented by Obagi Register here https://lnkd.in/edF9cB5X
-
Drew Fine shared thisThe first of a series of intriguing webinars on our newest injectable offering. Link below to register if interested! https://lnkd.in/erAkUuB4Drew Fine shared thisThe Science Of Skin: OBAGI® Saypha ChIQ™ with Dr. Suzan Obagi Gain expert insight into Obagi®ChIQ™ HA Filler through a discussion led by Dr. Suzan Obagi and Directors of Education. The session will review ChIQ™ science, patient before-and-afters featuring Obagi skincare, and holistic treatment planning to support comprehensive, results-driven outcomes. Date & Time: August 19th @ 2pm ET/ 11am PT REGISTER IN ADVANCE HERE: https://lnkd.in/g48dw4zS
-
Drew Fine reposted thisDrew Fine reposted this🚨 We're Hiring – Orlando, FL! 🚨 I'm looking for a seasoned, high-performing sales rockstar to join my team in Orlando, FL, representing both medical skincare and injectables. This is an incredible opportunity for someone who: ✨ Has a proven track record of exceeding sales goals ✨ Thrives in a competitive, high-performance environment ✨ Is passionate about aesthetics and building strong customer relationships ✨ Wants to be part of an amazing, supportive team with significant growth opportunities 💰 Outstanding compensation for the right candidate. If you—or someone in your network—is ready for the next step in an exciting aesthetics sales career, send me a message or reach out ASAP! Please feel free to share this post with anyone who would be a great fit!
-
Drew Fine reposted thisDrew Fine reposted thisAt OBAGI Medical, we're solidifying ourselves as a comprehensive aesthetic partner capable of supporting physicians and patients throughout the entire treatment journey, rather than presenting skincare and injectables as separate conversations. If you're ready to work for the #1 company in aesthetics spanning skincare, injectables, and longevity solutions, apply for this amazing opportunity in my Southeast region's Knoxville/Chattanooga territory!
-
Drew Fine shared thisNothing makes a mid-June day quite as exciting as an FDA approval! Hard to believe a year ago the idea that Obagi would be launching 2 new injectable products and carving a new mega brand path was still just an concept on paper. One acquisition of Novaestiq, 2 FDA approvals, exciting new skincare innovation, and some amazing new team members later and we are rolling! Thank you and congratulations to our partners Croma-Pharma as well for their hard work that led to the approval for these wonderful products.Drew Fine shared thisWe are thrilled to announce FDA approval for Obagi® saypha® ChIQ™, further expanding our growing injectable portfolio in the U.S. This new hyaluronic acid filler is designed for precision cheek augmentation and midface contouring. Following the strong momentum of saypha® MagIQ™, this approval solidifies Obagi’s position at the intersection of advanced skincare and clinical aesthetics. Read the full release here: https://lnkd.in/gCwGPrGQObagi Medical Announces FDA Approval of Obagi® saypha® ChIQ™ Injectable Hyaluronic Acid GelObagi Medical Announces FDA Approval of Obagi® saypha® ChIQ™ Injectable Hyaluronic Acid Gel
-
Drew Fine reposted thisThank you to Rachel Brown and Beauty Independent for such a thoughtful piece on the Obagi–Bridgepoint Group transaction. As I told Rachel, this isn't a trend — it's a fundamental shift toward brands that deliver real outcomes, and it's exactly where Obagi sits. #beauty #aesthetics #obagi https://lnkd.in/e_nqiT-hObagi Medical Sells To Bridgepoint For $460M As Beauty's Ties To Aesthetics DeepenObagi Medical Sells To Bridgepoint For $460M As Beauty's Ties To Aesthetics Deepen
-
Drew Fine reposted thisFour years ago, Hind and I started Waldencast with a simple conviction: that purpose-driven brands, given the right platform at the right moment, can become something extraordinary. Today, that conviction reached a milestone I'm enormously proud of. We've agreed to sell Obagi Medical to Bridgepoint Group — and Hind and I will be transitioning to lead Obagi into its next chapter alongside them. I won't pretend this is a small moment. Building Obagi into the world's first aesthetics "megabrand," launching Saypha MagIQ, taking it global — that was the work of an exceptional team, and every bit of today belongs to them. But here's what I keep coming back to: this isn't an ending dressed up as a beginning. It's a real beginning. Bridgepoint brings a platform, a depth of expertise, and a portfolio — including Laboratoires Vivacy — that gives Obagi room to become even more than it is today. Choosing to lead it forward, rather than hand it off, is the truest way I know to say I believe in what's next. And for Waldencast and Milk Makeup, this is a step into focus and strength — a stronger balance sheet, more room to invest, and a brand with extraordinary momentum under Rassi and the team. What I've learned over these four years is that the work was never really about the transactions. It was about the people who made them possible, and the brands worth fighting for. I'm walking into this next chapter more energized than I've been in a long time. We're at a moment where beauty, aesthetics, wellness, and longevity are converging into a single story about how people want to live. That's the opportunity ahead — and I couldn't be more excited to keep building into it. To the teams who got us here: thank you. The best is still in front of us. #beauty #aesthetics #wellness https://lnkd.in/eDErCUDNWaldencast Announces Sale of Obagi Medical to BridgepointWaldencast Announces Sale of Obagi Medical to Bridgepoint
-
Drew Fine reposted thisDrew Fine reposted thisAt RealSelf’s Real Talk Summit, Obagi Medical took part in an important conversation shaping the future of aesthetics. Justin Giouzepis (CMO) and Julia Silva Whelan (Senior Director of Commercial Strategy) joined Minou Clark (CEO, RealSelf) to discuss how Obagi is moving beyond HA injectables, leveraging skin quality, science, and our legacy to enhance performance and improve long-term patient outcomes.
-
Drew Fine shared this“These data points represent clinical and real-world results from our newest Obagi innovations,” stated Drew Fine, U.S. General Manager, Professional Channel. “Obagi Saypha® MagIQ™ and NU-GEN™ Cellular Renewal Serum represent meaningful advances that support practice success and highlight the benefits of looking at Obagi injectable and skincare solutions.” ObagiObagi Medical Shares New Data on Recent Innovations at Music City Symposium for Cosmetic Advances & Laser Education (SCALE) MeetingObagi Medical Shares New Data on Recent Innovations at Music City Symposium for Cosmetic Advances & Laser Education (SCALE) Meeting
-
Drew Fine liked thisDrew Fine liked thisThe Science Of Skin: Engineering Innovation in Obagi® HA Fillers Join David Kuroki-Hasenöhrl, PhD, Director of Development at Croma-Pharma, for an expert overview of Obagi® Saypha® ChIQ and MagIQ, including MACRO Core technology, HA filler performance properties, and key clinical evidence. Date & Time: Wednesday September 2nd; 12PM ET/9AM PT REGISTER NOW: https://lnkd.in/gnaifg3a
-
Drew Fine liked thisDrew Fine liked thisI’m thrilled to share that I’ve officially joined Takeda as Senior Vice President & Head of the US Gastrointestinal & Inflammation Business Unit here in Cambridge! Takeda has long been a pioneer in transforming care for patients living with GI and inflammatory conditions. Joining this remarkable team at such a pivotal moment—building on the incredible momentum of 2026—is a true privilege. I look forward to partnering with Rhonda Janice Pacheco and our exceptional teams across the US to push boundaries, accelerate innovation, and deliver life-changing impact for the patients and communities we serve. Here’s to the next chapter of growth, leadership, and bold possibilities!
-
Drew Fine liked thisDrew Fine liked thisEvery hyaluronic acid syringe starts with the same foundation. Raw hyaluronic acid is only the beginning. Through scientific development, gel design and manufacturing, distinct characteristics can be developed for different anatomical areas and treatment objectives. At Croma-Pharma, this scientific approach is supported by nearly 50 years of expertise in hyaluronic acid technologies and the manufacture of more than 130 million syringes. ¹ Hyaluronic acid raw material complies with the current version of the European Pharmacopoeia and is supported by the respective EDQM Certificate of Suitability. Data on file.
-
Drew Fine liked thisDrew Fine liked thisI built a med spa chain, the software a lot of you run it on, and a conference that trains the whole team. Same job the whole time: make aesthetics scalable without getting sloppy. Juvly started as one clinic in Columbus in 2014. It is multi-state now. That only works if the training is standardized. You cannot scale taste. You can scale a protocol. I built Aesthetic Record because the clinic outgrew its systems. People treat software like the product. It is not. Software is what you reach for when the practice is already bigger than the way you run it. Aesthetic Next is Dallas, Sept 10–13. Clinical and business in the same room, because a great injector with a broken practice still fails. I will write about the clinical side, the ops side, and the parts that get you investigated. If you run a practice, or want to, this is for you.
-
Drew Fine liked thisDrew Fine liked thisWe’re excited to invest in Obagi alongside Bridgepoint and pleased to make this the first investment from Gore Range Fund III. Obagi is one of the most recognized names in physician-dispensed skincare, with a decades-long history at the intersection of dermatology, aesthetics, and consumer health, making this investment a natural extension of Gore Range Capital’s longstanding focus on skin health and a strong reflection of the expertise, relationships, and ecosystem we’ve built in the space. We look forward to supporting Bridgepoint Group, the Obagi leadership team, and the broader organization in this next phase of growth. Read more here: https://lnkd.in/gbyCrumVGore Range Capital Announces Inaugural Fund III Investment in Obagi MedicalGore Range Capital Announces Inaugural Fund III Investment in Obagi Medical
-
Drew Fine liked thisAs we grow Gore Range Capital, we are increasing our focus on the growing intersection of longevity, wellness and skin health. Obagi is an ideal first investment for our new fund and we are thrilled to partner with Bridgepoint to help Obagi bring Innovations to its patients and customers.Drew Fine liked thisWe’re excited to invest in Obagi alongside Bridgepoint and pleased to make this the first investment from Gore Range Fund III. Obagi is one of the most recognized names in physician-dispensed skincare, with a decades-long history at the intersection of dermatology, aesthetics, and consumer health, making this investment a natural extension of Gore Range Capital’s longstanding focus on skin health and a strong reflection of the expertise, relationships, and ecosystem we’ve built in the space. We look forward to supporting Bridgepoint Group, the Obagi leadership team, and the broader organization in this next phase of growth. Read more here: https://lnkd.in/gbyCrumVGore Range Capital Announces Inaugural Fund III Investment in Obagi MedicalGore Range Capital Announces Inaugural Fund III Investment in Obagi Medical
Honors & Awards
-
Aesthetic Industry Association Leadership Award
Aesthetic Industry Association
-
Top 25 DTC Marketer of the Year
DTC Perspectives
-
PM 360 ELITE AWARD WINNER 2016
PM 360
Other similar profiles
Explore more posts
-
AllSci Corp.
AllSci Daily Brief | 2 Apr 2026 FDA approves Eli Lilly's oral GLP-1 Foundayo for weight loss Eli Lilly won US FDA approval for its oral GLP-1 therapy Foundayo (orforglipron) for weight loss. The approval marks Lilly’s second cleared obesity medicine and establishes orforglipron as the first non-peptide small-molecule GLP-1 receptor agonist to reach the US market for weight management, following Novo Nordisk’s peptide-based oral semaglutide, which was approved in 2025. In contrast with Lilly’s domination of injectable incretin drugs, in the oral space the company must now convince patients that the greater convenience of Foundayo offsets a modestly lower weight loss efficacy versus Novo’s oral Wegovy. Full story here: https://lnkd.in/eCwJvJJ4 Also today: Merck boosts antibody discovery capability through USD 838m partnership with Infinimmune OpenProtein.AI, Boehringer Ingelheim expand AI discovery partnership Zai Lab and Amgen collaborate on DLL3-targeting dual mechanism strategy for SCLC Gan & Lee's once-weekly basal insulin beats insulin glargine and degludec in Phase III type 2 diabetes trials Follow AllSci for full coverage: https://allsci.com/news/ #biotech #pharma #drugdevelopment #biotechnews #lifesciences #biopharma
-
Patrick Urban
The conversation in medical aesthetics has fundamentally shifted from correction to personalization. Today's patients are more informed than ever. They show up with clear goals and thoughtful questions, informed by social media, their peers and society’s increasing willingness to talk openly about aesthetic choices and treatments. That shift has raised the bar for providers and forced our industry to rethink how we develop solutions. Innovation today isn't just about developing new products. It's about creating solutions that enable providers to deliver personalized treatment plans, educate patients effectively and build lasting relationships rooted in trust. That’s why at Merz Aesthetics, we’re investing in provider education, developing products that support a range of treatment approaches and creating tools to help providers have deeper conversations with their patients. Because the future of medical aesthetics isn’t one-size-fits-all – it’s personal. #MerzAxEmployee #MerzAesthetics #MedicalAesthetics #Innovation
3 Comments
Explore top content on LinkedIn
Find curated posts and insights for relevant topics all in one place.
View top contentOthers named Drew Fine
77 others named Drew Fine are on LinkedIn
See others named Drew Fine